Amgen to spend $13.4B on Celgene psoriasis drug Otezla
Celgene will unload the psoriasis treatment Otezla for $13.4 billion to help make its acquisition by fellow drugmaker Bristol-Myers pass regulatory muster.
More from Virginia Business
Virginia Lawyers Weekly
Securities claims can't be based on puffery, boasting
Virginia Business
•
Dec 5, 2022
Virginia Lawyers Weekly
022-2-247 -- Zeigler v. Eastman Chemical Company
Virginia Business
•
Dec 5, 2022
Virginia Lawyers Weekly
Court clarifies 'statutory employees' exception
Virginia Business
•
Dec 5, 2022
Virginia Lawyers Weekly
022-2-243 -- Capps v. Newmark Southern Region LLC
Virginia Business
•
Dec 5, 2022